1. Biodexa announces $10 million public offering of securities. 2. Offering includes 157,000 ADS Units and nearly 2.9 million pre-funded units. 3. Proceeds will fund development programs and working capital. 4. Offering expected to close on December 19, 2025, pending conditions. 5. Company developing pipeline targeting unmet medical needs in various diseases.
FAQ
Why Bullish?
The offering is aimed at raising capital for growth, which is generally viewed positively. Similar prior offerings in biotech have historically led to short-term price increases when funds are allocated effectively.
How important is it?
The offering's proceeds can substantially support ongoing clinical programs, heightening market interest, particularly given Biodexa's innovative pipeline.
Why Short Term?
The public offering may lead to increased liquidity and market presence in the short term. Past fundraises in biotech have caused immediate investor interest and stock price movement.
Biodexa Pharmaceuticals PLC Announces Pricing of $10 Million Public Offering
On December 18, 2025, Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs, announced the pricing of a public offering aimed at raising approximately $10 million.
Details of the Public Offering
The offering consists of a combination of:
- 157,000 ADS Units: Each unit will include one American depositary share (representing 100,000 of the Company’s ordinary shares) and two Series L warrants, each allowing the purchase of one ADS.
- 2,891,781 Pre-Funded Units: Each Pre-Funded Unit will comprise one pre-funded warrant to purchase one ADS and two Series L Warrants.
The combined public offering price for each ADS Unit is set at $3.28, while each Pre-Funded Unit will be priced at $3.2799. Importantly, the securities in these units are immediately separable and will be issued separately.
Warrant Expiration and Financial Projections
Each Series L Warrant is structured to expire five years from the issue date and is immediately exercisable at the price of $3.28 per ADS. The total gross proceeds anticipated from this offering, before subtracting fees and expenses, will be approximately $10 million.
The net proceeds from this public offering will be allocated toward funding Biodexa’s development programs, working capital requirements, and other corporate functions.
Closing and Regulatory Compliance
Expectations are set for the offering to close on December 19, 2025, pending the fulfillment of customary closing conditions. Maxim Group LLC is serving as the sole placement agent for this public offering.
The securities are being offered under an effective registration statement on Form F-1 (File No. 333-291598) declared effective by the U.S. Securities and Exchange Commission (SEC) on December 17, 2025. A final prospectus associated with this offering will be available on the SEC's website.
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC, trading on NASDAQ under the symbol BDRX, is committed to building a pipeline of innovative therapeutic products catering to diseases with significant unmet medical needs. Current lead development programs include:
- eRapa: Targeting Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer.
- Tolimidone: Aiming to treat Type 1 Diabetes.
- MTX110: Focused on aggressive rare/orphan brain cancer indications.
Biodexa employs three proprietary drug delivery technologies that enhance the bio-delivery and bio-distribution of its pharmaceutical products, with its headquarters and R&D facilities located in Cardiff, UK.
Forward-Looking Statements
This announcement includes forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements reflect management’s beliefs and interpretations as of the date of this release. Actual results could differ due to various risks and uncertainties.
For further information or inquiries about this offering, please contact Biodexa Pharmaceuticals PLC, attention Stephen Stamp, CEO/CFO, at +44 (0)29 20480 180 or visit www.biodexapharma.com.